Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Deitelzweig

Internal Medicine New Orleans, LA Medical Doctor

NPI 1811954910 CMS profile 700284

1514 Jefferson Hwy, New Orleans, LA 70121

Open in the dashboard

General payments

$938,685

419 records reported · program years 2019–2025

Research payments

$7,150

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Deitelzweig of New Orleans, LA is reported in the CMS Open Payments database as having received $938,685 across 419 general payments and $7,150 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $174,896 49
2024 General $153,373 72
2023 General $100,723 44
2022 General $99,293 33
2022 Research $7,150 1
2021 General $102,631 22
2020 General $81,854 37
2019 General $225,915 162

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Deitelzweig
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Steven Deitelzweig were reported at $174,896. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Steven Deitelzweig Internal Medicine median Middle half National median
2019 $225,915 $159 $48–$570 $163
2020 $81,854 $119 $33–$402 $114
2021 $102,631 $135 $37–$521 $132
2022 $99,293 $141 $42–$496 $149
2023 $100,723 $149 $45–$519 $160
2024 $153,373 $154 $47–$537 $164
2025 $174,896 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $427,635 186 payments
  2. E.R. Squibb & Sons, L.L.C. $379,919 140 payments
  3. Pfizer International LLC $61,563 21 payments
  4. Gilead Sciences, Inc. $30,111 40 payments
  5. Pfizer Limited $20,437 6 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $9,175 8 payments
  7. Portola Pharmaceuticals, Inc. $3,465 6 payments
  8. Pfizer S.A.S. $3,213 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,716 3 payments
  10. AstraZeneca Pharmaceuticals LP $1,171 3 payments
  11. Other $279 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $536,307 88 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $249,290 77 payments
  3. Travel and Lodging $124,048 173 payments
  4. Honoraria $24,044 5 payments
  5. Food and Beverage $4,996 76 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $412,875 178 payments
  2. ELIQUIS Cardiovascular $105,980 53 payments
  3. Veklury $28,545 32 payments
  4. PAXLOVID $13,408 7 payments
  5. PRISTIQ $4,380 1 payment
  6. ANDEXXA Hematology/Neurology $3,465 6 payments
  7. XIFAXAN $1,716 3 payments
  8. RELISTOR $1,666 2 payments
  9. ANDEXXA Rare Disease $1,050 2 payments
  10. PLENVU $833 1 payment
  11. Other $1,112 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $7,150 1 payment

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$6,254

Medicare's payments for the services billed

Medicare patients

23

Average age 75

Services billed

74

11 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 70%
Diabetes 57%
Heart failure 57%
Depression 57%
Arthritis 52%
Alzheimer's or dementia 52%
Ischemic heart disease 48%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $68,345
  • E.R. Squibb & Sons, L.L.C. $7,310
  • PFIZER INTERNATIONAL LLC $3,750
$79,406 — —
Veklury
  • Gilead Sciences, Inc. $15,981
$15,981 — —
PAXLOVID
  • PFIZER INC. $10,370
$10,370 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record